Section Arrow
NLSP.NASDAQ
- Nls Pharmaceutics Ltd
Quotes are at least 15-min delayed:2025/07/20 13:11 EDT
Regular Hours
Last
 2.22
-0.03 (-1.33%)
Day High 
2.31 
Prev. Close
2.25 
1-M High
3.0799 
Volume 
159.67K 
Bid
2.21
Ask
2.24
Day Low
2.19 
Open
2.22 
1-M Low
2.06 
Market Cap 
11.04M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.25 
20-SMA 2.39 
50-SMA 2.16 
52-W High 15.588 
52-W Low 1.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.63/1.13
Enterprise Value
11.36M
Balance Sheet
Book Value Per Share
-0.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 13:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.